ClinicalTrials.gg
Not yet recruitingNCT06872580Updated Mar 12, 2025

A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors

A Phase 1 interventional study of QLS1209 and QLS1209 in Advanced Solid Tumor, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
149
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to assess the safety and tolerability of QLS1209 alone in patients with eligible advanced solid tumors,determine the maximum tolerated dose (MTD) or maximum drug dose(MAD)of QLS1209, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer to participate in this clinical study; completely understand and know this study as well as sign the form (ICF);
  • Age ≥ 18 years when ICF is signed;
  • performance status of 0 or 1;
  • Expected survival ≥ 3 months;
  • advanced malignant solid tumors who have failed standard treatment or have received no standard treatment;
  • a) CCNE1 amplification determined by tumor or plasma next generation sequencing (NGS) or fluorescence in-situ hybridization (FISH); b) FBXW7 mutation determined by tumor or plasma NGS; c) PPP2R1A mutation determined by tumor or plasma NGS;
  • Subjects with at least one evaluable tumor lesion (dose-escalation stage) or at least one measurable tumor lesion (dose-expansion stage) according to v1.1;

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with PKMYT1 inhibitors;
  • Received chemotherapy, biological therapy, endocrine therapy, immunotherapy, monoclonal antibody and other anti-tumor therapies within 4 weeks before the first dose of the drug, special conditions are as follows:

    1. Including subjects who received oral fluorouracils, small molecule targeted drugs, radiotherapy or traditional Chinese medicines with anti-tumor indications within 2 weeks before the first dose;
    2. Including subjects who received treatment with mitomycin or nitrosoureas within 6 weeks before the first dose;
    3. Including subjects who received cell-based therapy or anti-tumor vaccines within 8 weeks before the first dose.
  • Presence of uncontrolled or symptomatic central nervous system (CNS) , or presence of or spinal cord compression due to metastases before signing the ICF. Exceptions: Subjects with symptomatic who have been treated and radiologically stable (defined as 2 brain images of the same imaging modalities, both acquired after treatment for brain metastases with an interval of at least 4 weeks, showing no intracranial progression by comparison) for ≥ 4 weeks before the first dose of the investigational drug, and have discontinued systemic sex hormone (any dose) therapy for > 2 weeks;
  • Subjects with uncontrollable exudate or transudate (thoracic cavity, pericardium and abdominal cavity);
  • Subjects with other active malignant tumors within 3 years before being included in the study (from the time of signing ICF), except for the following: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ, breast cancer in situ and other malignant tumors that have been treated without disease evidence within > 2 years and do not require continuous treatment; Known to be allergic to the investigational drug or any of its ;
  • Subjects with current interstitial lung disease, pneumoconiosis, radiation pneumonitis, severely impaired lung function, etc. that may interfere with the monitoring and treatment of suspected drug-related pulmonary toxicity as judged by the investigator;
  • Subjects who are unable to swallow and retain oral drugs, or have active gastrointestinal diseases (including inflammatory bowel disease and intestinal obstruction) and other conditions that seriously affect drug absorption as judged by the investigator;
  • Subjects who have other serious physical or psychiatric diseases or laboratory test abnormalities that may increase the risk of participating in the study or interfere with the results of the study, and are considered unsuitable for participation in the study by the investigator;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
149 participants (estimated)

Study arms

  • Experimental
    QLS1209 mono dose escalation and optimization

    Drug: QLS1209

Interventions

  • DrugQLS1209

    Levels of QLS1209 will be explored in dose escalation, and determine the maximum tolerated dose.

  • DrugQLS1209

    Every 21 days is one cycle.1-3 dose levels of QLS1209 will be explored in dose optimization, and determine the recommended dose (RD) of QLS1209 and evaluate the preliminary anti-tumor activity of QLS1209.

06

What researchers measure

Primary outcomes

  1. AEs, TEAEs, TRAEs, SAEs

    Incidence, severity and relevance to the trial drug of adverse events (AEs), treatment-related adverse events (TEAEs), treatment-related adverse events (TRAEs) and serious adverse events (SAEs)

    Time frame: up to 2 years

  2. MTD/MAD

    maximum tolerated dose/ maximum drug dose

    Time frame: Up to 21 days after the first dose

  3. RP2D

    recommended phase II dose

    Time frame: Up to 21 days after the first dose

Secondary outcomes

  1. Tmax

    Time to Reach Maximum (peak) Plasma Concentration Following Drug Administration

    Time frame: up to 2 years

  2. Cmax

    Maximum Plasma Drug Concentration

    Time frame: up to 2 years

  3. ORR

    Objective Response Rate

    Time frame: up to 2 years

  4. DoR

    Duration of Response

    Time frame: up to 2 years

  5. DCR

    Disease Control Rate

    Time frame: up to 2 years

  6. PFS

    Progression-free Survival

    Time frame: up to 2 years

  7. OS

    Overall Survival

    Time frame: up to 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Apr 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 12, 2025
StartEst.
Apr 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2028
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06872580
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
Apr 2025 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Mar 12, 2025

Study contacts

Xiaohua Wu, PhD
Contact
JJYIN555@163.com
021-64175590-88503

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion